主要目的：健康受试者空腹状态下，经口吸入单次给药环索奈德气雾剂（受试制剂T，上海上药信谊药厂有限公司生产，规格：80μg/揿）与环索奈德气雾剂（参比制剂R，Covis Pharma Gmbh生产，商品名：Alvesco®，规格：80μg/揿）后，考察空腹条件下受试制剂与参比制剂在人体内的吸收速度和吸收程度，评价受试制剂与参比制剂是否具有生物等效性。次要目的：观察受试制剂环索奈德气雾剂和参比制剂环索奈德气雾剂（Alvesco®）在健康受试者中的安全性。

开始日期2023-12-12

申办/合作机构

上海上药信谊药厂有限公司

EUCTR2020-002208-37-DK / Unknown status临床2期IIT

The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov

开始日期2021-04-29

申办/合作机构-

NCT04920838 / Recruiting临床2/3期IIT

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Coverage Africa is a nested study in the large Anticov platform trial that aims to generate data on new early treatment strategies for mild/moderate COVID-19 patients in resource-limited-settings to reduce the number progressing to severe forms requiring hospitalization, thereby relieving the burden on health care systems and contributing to "flattening the curve" in contexts where none pharmaceutical intervention such as quarantine are difficult to implement in large urban settings. Treating early when the virus is still present might also limit transmission. Coverage Africa will be conducted in Guinea and Burkina Faso.
The main objective is to conduct an open-label, multicenter, randomized, adaptive platform trial to test the safety and efficacy of several marketed products, including antiviral therapies versus control in mild/moderate of coronavirus disease 2019 (Covid-19) in resource-limited-settings.
The study aims to recruit 600 patients in both countries, one site in Guinea and two sites in Burkina Faso.
The current assessed treatments are now the association of Fluoxétine/Budésonide compared with a control arm: paracetamol.
The adaptive design trial will allow for the removal of drugs, or the addition of new study arms when new data becomes available. Data on the primary efficacy parameters and safety will be integrated with the primary endpoint based on an oxygen saturation percentage (SpO2) ≤ 93% or death within 14 days after randomization to treatment, including death for any reason.
Study will run until August 2022. However, with the proposed adaptive design, the study could also be interrupted for success earlier than planned with the identification of a treatment that significantly reduces hospitalization rate as evidence by results from the primary endpoint.

开始日期2021-04-12

申办/合作机构

ANRS, Emerging Infectious Diseases

[+4]

100 项与环索奈德相关的临床结果

登录后查看更多信息

100 项与环索奈德相关的转化医学

登录后查看更多信息

100 项与环索奈德相关的专利（医药）

登录后查看更多信息

390

项与环索奈德相关的文献（医药）

2024-01-22·Current pharmaceutical biotechnology

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.

Article

作者: Katharine Hodel ; Ananda Fonseca ; Islania Barbosa ; Caio Medina ; Brenda Alves ; Carine Maciel ; Daniel Nascimento ; Gessualdo Oliveira-Junior ; Lorena Pedreira ; Monielly de Souza ; Ana Leonor Godoy

Important physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the prevalence, severity, and lethality of the disease. Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin. Similarly, these differences between healthy people and obese people can be correlated to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the absorption and distribution of the vaccine that will be lower than desired or can be linked to the inflammatory state in obese patients, which can influence the humoral immune response. Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.

2024-01-01·PloS one

Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan.

Article

作者: Haruka Shida ; Maki Komamine ; Kazuhiro Kajiyama ; Takashi Waki ; Hotaka Maruyama ; Yoshiaki Uyama

OBJECTIVE:

Prescription trends and patterns of anti-COVID-19 drugs in hospitalized patients were examined based on real world data to understand the use of anti-COVID-19 drugs in clinical practice in Japan.

DESIGN:

The longitudinal and cross-sectional study was conducted utilizing data from January 1, 2019 to December 31, 2021 of the MID-NET® medical information database, which stored the electronic medical records, administrative claim data, and diagnosis procedure combination data of patients in Japan.

PARTICIPANTS:

Hospitalized patients with a COVID-19-related diagnosis who received at least one anti-COVID-19 drug between April 1, 2020 and December 31, 2021.

EXPOSURES:

The following 14 drugs were included in this study: remdesivir, baricitinib, combination product of casirivimab and imdevimab, favipiravir, dexamethasone, ivermectin, azithromycin, nafamostat mesylate, camostat mesylate, ciclesonide, tocilizumab, sarilumab, combination product of lopinavir and ritonavir, and hydroxychloroquine.

RESULTS:

We identified 5,717 patients hospitalized with COVID-19 and prescribed at least one anti-COVID-19 drug. The entire cohort generally included patients over 41-50 years and more males. The most common prescription pattern was dexamethasone monotherapy (22.9%), followed by the concomitant use of remdesivir and dexamethasone (15.0%), azithromycin monotherapy (15.0%), remdesivir monotherapy (10.2%), and nafamostat mesylate monotherapy (8.5%). However, an often prescribed anti-COVID-19 drug differed depending on the period.

CONCLUSIONS AND RELEVANCE:

This study revealed the real-world situation of anti-COVID-19 drug prescriptions in hospitalized COVID-19 patients in Japan. A prescribed drug would depend on the latest scientific evidence, such as efficacy, safety, and approval status, at the time of prescription. Understanding the prescription of anti-COVID-19 drugs will be important for providing the most up-to-date treatments to patients and evaluating the benefit and/or risk of anti-COVID-19 drugs based on the utilization of an electronic medical record database.

2023-10-30·Drug discoveries & therapeutics

Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.

Article

作者: Manabu Suzuki ; Akihiro Matsunaga ; Tohru Miyoshi-Akiyama ; Junko Terada-Hirashima ; Kenji Sadamasu ; Mami Nagashima ; Jin Takasaki ; Shinyu Izumi ; Masayuki Hojo ; Yukihito Ishizaka ; Haruhito Sugiyama

During an earlier multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of high-dose inhaled ciclesonide in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19), we observed that worsening of shadows on CT without worsening of clinical symptoms was more common with ciclesonide. The present study sought to determine if an association exists between worsening CT shadows and impaired antibody production in patients treated with inhaled ciclesonide. Eighty-nine of the 90 patients in the original study were prospectively enrolled. After exclusions, there were 36 patients each in the ciclesonide and control groups. We analyzed antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein at various time points. Changes in viral load during treatment were compared. There was no significant difference in age, sex, body mass index, background clinical characteristics, or symptoms between the two groups. Although evaluation on day 8 suggested a greater tendency for worsening shadows on CT in the ciclesonide group (p = 0.072), there was no significant difference between them in the ability to produce antibodies (p = 0.379) or the maximum antibody titer during the clinical course. In both groups, worsening CT shadows and higher viral loads were observed on days 1-8, suggesting ciclesonide does not affect clearance of the virus (p = 0.134). High-dose inhaled ciclesonide did not impair production of antibodies against SARS-CoV-2 or affect elimination of the virus, suggesting that this treatment can be used safely in patients with COVID-19 patients who use inhaled steroids for asthma and other diseases.

项与环索奈德相关的新闻（医药）

2024-04-02

·Pharma CMC

信诺制药即将登场CMC-China博览会——专业的吸入制剂CMO

2024年8月15-16日苏州国际博览中心B-D馆展会背景CMC-China博览会以研发为主线，串联医药上下游，以圈友信任为纽带，帮助大家“寻找到下一个合作伙伴”，自2019年以来，我们已成功举办5届，影响力持续提升，在中国医药产业创新发展的大浪潮中，茁壮成长，已经成为国内生物医药领域大型博览会的知名品牌。企业邀约信诺制药——专业的吸入制剂CMO！欢迎莅临D馆-C05-1展位，现场参观，交流分享！↓↓扫描下方二维码免费报名01 公司简介天津信诺制药有限公司隶属于天津医药集团，坐落于天津经济技术开发区。专注于吸入粉雾剂（DPI）的研发和生产，多年来积累了吸入粉雾剂产业化生产经验，可提供从吸入制剂生产、吸入装置、吸入产品注册等全链条定制化服务与合作。天津信达制药有限公司隶属于天津医药集团，坐落于天津经济技术开发区。专注于吸入喷雾剂（SMI）的研发和生产，是国内第一家取得吸入喷雾剂给药装置器械注册文号的企业，拥有吸入喷雾剂产品生产和检验所需的全套高端设备。02 卓越的生产质量管理体系拥有独立的商业化生产基地，用于生产吸入粉雾剂(DPI)和吸入喷雾剂(SMI)。符合GMP标准，并由专门的生产团队运营。天津市企业重点实验室天津市创新型中小企业03 合作模式合作方式包括：投资合作、研发阶段合作、生产阶段合作研发阶段技术包转移硫酸沙丁胺醇吸入粉雾剂沙美特罗替卡松粉吸入粉雾剂环索奈德吸入粉雾剂布地奈德吸入粉雾剂检验服务吸入专项：空气动力学、喷雾模式检测装置检测：三维尺寸测量、气流阻力测量装置合作单储库型吸入粉雾剂装置双储库型吸入粉雾剂装置吸入喷雾剂装置生产阶段粉碎气流粉碎单批最大5KG配置干粉混合无菌液体灌装干粉定量灌装无菌液体灌装装置组装年产能千万只04 合作联系周女士 13306586060嵇女士 13625705846↓↓扫描下方二维码免费报名关于CMC-China博览会

2024-03-18

·信狐药迅

江苏先声注射用苏维西塔单抗、第一三共Datopotamab Deruxtecan提交上市申请| 新受理（3.11-3.17）

本周药品注册受理数据，分门别类呈现，一目了然。(3.11-3.17）新药上市申请药品名称企业注册分类受理号盐酸来罗西利片Genor Biopharma(USA), Inc.1JXHS2400020注射用Datopotamab DeruxtecanDaiichi Sankyo Europe GmbH1JXSS2400026注射用苏维西塔单抗江苏先声生物制药有限公司1CXSS2400022聚乙二醇干扰素α-2b注射液厦门特宝生物工程股份有限公司2.2CXSS2400026聚乙二醇干扰素α-2b注射液厦门特宝生物工程股份有限公司2.2CXSS2400025聚乙二醇干扰素α-2b注射液厦门特宝生物工程股份有限公司2.2CXSS2400024聚乙二醇干扰素α-2b注射液厦门特宝生物工程股份有限公司2.2CXSS2400023Belzutifan片MERCK SHARP & DOHME (UK) LIMITED5.1JXHS2400021环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400019环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400018新药临床申请药品名称企业注册分类受理号BAT6005注射液百奥泰生物制药股份有限公司1CXSL2400189BAT1308注射液百奥泰生物制药股份有限公司1CXSL2400188ABBV-400注射用粉末AbbVie Inc.1JXSL2400060ABP1618片上海爱博医药科技有限公司1CXHL2400285ABP1618片上海爱博医药科技有限公司1CXHL2400284FC084CSA片中山医诺维申新药研发有限公司1CXHL2400283FC084CSA片中山医诺维申新药研发有限公司1CXHL2400282Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400064Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400063SHR-4849注射液苏州盛迪亚生物医药有限公司1CXSL2400186注射用YL205苏州宜联生物医药有限公司1CXSL2400185注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2400183F230片北京康蒂尼药业股份有限公司1CXHL2400281F230片北京康蒂尼药业股份有限公司1CXHL2400280F230片北京康蒂尼药业股份有限公司1CXHL2400279替古索司他片信达生物制药(苏州)有限公司1CXHL2400278替古索司他片信达生物制药(苏州)有限公司1CXHL2400277替古索司他片信达生物制药(苏州)有限公司1CXHL2400276CU-10101软膏科笛生物医药(无锡)有限公司1CXHL2400275CU-10101软膏科笛生物医药(无锡)有限公司1CXHL2400274CU-10101软膏科笛生物医药(无锡)有限公司1CXHL2400273CU-10101软膏科笛生物医药(无锡)有限公司1CXHL2400272BI 1839100 片Boehringer Ingelheim International GmbH1JXHL2400062SSGJ-707注射液沈阳三生制药有限责任公司1CXSL2400184SI-B001双特异性抗体注射液四川百利药业有限责任公司1CXSL2400182金纳单抗注射液长春金赛药业有限责任公司1CXSL2400179ER2001注射液艾码生物科技(南京)有限公司1CXSL2400181INNA1605软膏武汉亿诺药业有限公司1CXHL2400271INNA1605软膏武汉亿诺药业有限公司1CXHL2400270MK-1084片默沙东研发(中国)有限公司1CXHL2400267MK-1084片默沙东研发(中国)有限公司1CXHL2400266ABP2111Na片上海爱博医药科技有限公司1CXHL2400265ABP2111Na片上海爱博医药科技有限公司1CXHL2400264BPYT-01胶囊百极优棠(广东)医药科技有限公司1CXHL2400269BPYT-01胶囊百极优棠(广东)医药科技有限公司1CXHL2400268SHR-9539注射液苏州盛迪亚生物医药有限公司1CXSL2400178SHR-9539注射液苏州盛迪亚生物医药有限公司1CXSL2400177温肺定喘颗粒山东康众宏医药科技开发有限公司1.1CXZL2400015鼻喷重组呼吸道合胞病毒疫苗(5型副流感病毒载体)广州思安信生物技术有限公司1.1CXSL2400180FTZ浓缩丸深圳前海吉奥健康科技有限公司1.1CXZL2400014呼吸道合胞病毒IN006二价mRNA疫苗深圳深信生物科技有限公司1.2CXSL2400187TAR-210Janssen Research & Development, LLC2.2JXHL2400065帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400059重组人绒促性素注射液苏州晟济药业有限公司3.3CXSL2400176仿制药申请药品名称企业注册分类受理号西咪替丁注射液苏州朗科生物技术股份有限公司3CYHS2400845复方聚乙二醇电解质散(儿童型)四川科伦药业股份有限公司3CYHS2400838硫酸阿托品注射液江苏开元药业有限公司3CYHS2400853普仑司特干糖浆济川药业集团有限公司3CYHS2400849溴吡斯的明缓释片上海上药中西制药有限公司3CYHS2400832小儿复方氨基酸注射液(19AA-I)湖北民康药业集团有限公司3CYHS2400830小儿复方氨基酸注射液(19AA-I)湖北民康药业集团有限公司3CYHS2400829盐酸左沙丁胺醇雾化吸入溶液石家庄四药有限公司3CYHS2400827盐酸麻黄碱注射液成都苑东生物制药股份有限公司3CYHS2400825倍他米松磷酸钠注射液吉林省辉南长龙生化药业股份有限公司3CYHS2400824拉米地坦片江苏恩华药业股份有限公司3CYHL2400059拉米地坦片江苏恩华药业股份有限公司3CYHL2400058钠钾镁钙注射用浓溶液辰欣药业股份有限公司3CYHS2400820法莫替丁注射液湖南柏齐鹤药物研发有限公司3CYHS2400817洛索洛芬钠口服溶液江西施美药业股份有限公司3CYHS2400809腺苷钴胺胶囊华益药业科技(安徽)有限公司3CYHS2400811复方托吡卡胺滴眼液山东辰欣佛都药业股份有限公司4CYHS2400860枸橼酸西地那非口腔崩解片济南高华制药有限公司4CYHS2400859盐酸尼卡地平注射液北京新美泰克医药科技有限公司4CYHS2400858吡仑帕奈片锦州奥鸿药业有限责任公司4CYHS2400857吡仑帕奈片锦州奥鸿药业有限责任公司4CYHS2400856孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400855孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400854枸橼酸氢钾钠颗粒浙江沣华医药科技有限公司4CYHS2400848二十碳五烯酸乙酯软胶囊人福普克药业(武汉)有限公司4CYHS2400847二十碳五烯酸乙酯软胶囊人福普克药业(武汉)有限公司4CYHS2400846玻璃酸钠滴眼液辅必成(上海)医药科技有限公司4CYHS2400844左氧氟沙星氯化钠注射液辽宁民康制药有限公司4CYHS2400843卡左双多巴缓释片精华制药集团股份有限公司4CYHS2400842卡左双多巴缓释片精华制药集团股份有限公司4CYHS2400841苯磺酸氨氯地平片华益药业科技(安徽)有限公司4CYHS2400840苯磺酸氨氯地平片华益药业科技(安徽)有限公司4CYHS2400839乳果糖口服溶液安徽四环科宝制药有限公司4CYHS2400836他达拉非片湘北威尔曼制药股份有限公司4CYHS2400852他达拉非片湘北威尔曼制药股份有限公司4CYHS2400851他达拉非片湘北威尔曼制药股份有限公司4CYHS2400850富马酸福莫特罗吸入溶液石家庄四药有限公司4CYHS2400837莫匹罗星软膏浙江众延医药科技有限公司4CYHS2400831盐酸氨溴索口服溶液黑龙江澳利达奈德制药有限公司4CYHS2400828富马酸伏诺拉生片重庆圣华曦药业股份有限公司4CYHS2400826瑞戈非尼片仁合熙德隆药业有限公司4CYHS2400835头孢托仑匹酯颗粒福安药业集团庆余堂制药有限公司4CYHS2400834头孢托仑匹酯颗粒福安药业集团庆余堂制药有限公司4CYHS2400833甲氨蝶呤注射液胜思(广州)制药科技有限公司4CYHS2400816甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400815甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400814吉非替尼片山东鲁抗医药股份有限公司4CYHS2400813孟鲁司特钠颗粒广州博济生物医药科技园有限公司4CYHS2400823苯磺酸氨氯地平片湖南状元制药有限公司4CYHS2400822苯磺酸氨氯地平片湖南状元制药有限公司4CYHS2400821盐酸伊立替康注射液吉斯美(武汉)制药有限公司4CYHS2400819盐酸伊立替康注射液吉斯美(武汉)制药有限公司4CYHS2400818醋酸加尼瑞克注射液广东粤和泽药物研究有限公司4CYHS2400808艾考糊精腹膜透析液山东齐都药业有限公司4CYHS2400807左氧氟沙星滴眼液河北合渡药业有限公司4CYHS2400806屈螺酮炔雌醇片武汉九珑人福药业有限责任公司4CYHS2400812注射用氟氧头孢钠浙江惠迪森药业有限公司4CYHS2400810进口申请药品名称企业注册分类受理号盐酸来罗西利片Genor Biopharma(USA), Inc.1JXHS2400020注射用Datopotamab DeruxtecanDaiichi Sankyo Europe GmbH1JXSS2400026ABBV-400注射用粉末AbbVie Inc.1JXSL2400060Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400064Balcinrenone达格列净胶囊AstraZeneca AB1JXHL2400063BI 1839100 片Boehringer Ingelheim International GmbH1JXHL2400062TAR-210Janssen Research & Development, LLC2.2JXHL2400065帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400059Belzutifan片MERCK SHARP & DOHME (UK) LIMITED5.1JXHS2400021环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400019环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400018他达拉非片Sawai Pharmaceutical Co., Ltd.5.2JYHS2400012中药相关申请药品名称企业注册分类受理号温肺定喘颗粒山东康众宏医药科技开发有限公司1.1CXZL2400015FTZ浓缩丸深圳前海吉奥健康科技有限公司1.1CXZL2400014不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市

2024-03-14

·梅斯医学

花粉过敏高发季又要来了

“草长莺飞二月天，拂堤杨柳醉春烟”。春天，正是山花烂漫之时，孩子们都迫不及待走出家门拥抱春天。可是每当这时候，一些孩子却被“花粉过敏”折磨得苦不堪言，鼻涕喷嚏不断，严重的甚至会出现哮喘症状，呼吸困难。花粉过敏又叫花粉症、枯草热，是一种因吸入外界花粉抗原而引起的过敏性疾病，春季为高发期。花粉过敏是特应性体质患者被花粉致敏后引起的一系列的病理生理过程。花粉过敏为过敏科常见病，且发病率逐年上升，严重影响人类健康。主要表现为呼吸道和结膜的卡他性炎症，可伴有皮肤及其它器官的病变。常见过敏原花粉过敏的“元凶”是花粉，自然界的花粉传播主要分风媒和虫媒两种形式。虫媒花粉，如油菜花、桃花、梨花的花粉，靠蝴蝶或蜜蜂等昆虫传播，特点是花朵鲜艳，带有芳香或其他气味，花粉颗粒较大，花粉量不多，不易四处播散，通常不会引起过敏。风媒花粉，如柏树、杨树、柳树、桦树、梧桐等的花粉，特点是花型小，花粉含量高，质量较轻，可以随风飞到很远的地方，风媒花粉是主要过敏原。临床表现1、花粉过敏性鼻炎：主要表现为阵发性喷嚏、清水样涕、鼻痒和鼻塞等症状。2、花粉过敏性结膜炎：眼痒，眼睑肿，出现黏液性分泌物。3、花粉过敏性皮疹：皮肤、耳朵等处瘙痒，皮肤出现风疹块、红色斑丘疹、以及湿疹等。4、花粉过敏性哮喘：阵发性咳嗽、呼吸困难，有白色泡沫样黏痰，甚至出现呼吸困难。过敏性鼻炎常用药物治疗1、糖皮质激素（1）鼻用激素：是AR的一线治疗药物，临床推荐使用。鼻用激素分为第一代（包括布地奈德、曲安奈德、丙酸倍氯米松、氟尼缩松）和第二代（包括糠酸莫米松、丙酸氟替卡松、糠酸氟替卡松、倍他米松、环索奈德），与第一代鼻用激素相比，第二代鼻用激素具有高亲脂性、与受体结合力强、抗炎活性更强、生物利用度低等特点。对于轻度AR和中‑重度间歇性AR，疗程不少于2周；对于中‑重度持续性AR是首选药物，疗程4周以上。由于AR存在黏膜最轻炎症持续状态，持续治疗或者最低维持剂量持续治疗对病情的长期控制效果明显优于间断治疗。一般不推荐在妊娠期和哺乳期使用鼻用激素。（2）口服糖皮质激素：是AR的二线治疗药物，临床需要慎重和酌情使用。对于症状严重难以控制的AR可考虑短期口服糖皮质激素。用法用量：剂量按患者体重计算（以泼尼松为例，剂量为0.5~1.0mg/kg），早晨顿服，疗程4~7d。注意全身使用糖皮质激素的不良反应，避免用于儿童、老年人以及有糖皮质激素使用禁忌证的患者。2、抗组胺药（1）口服抗组胺药：第二代抗组胺药为AR的一线治疗药物，可常规用于老年AR患者。这类药物起效快速，作用持续时间较长，能明显缓解鼻部症状特别是鼻痒、喷嚏和流涕，对合并眼部症状也有效，但对改善鼻塞的效果有限。用法用量：一般每天只需用药1次，疗程不少于2周。对花粉过敏的患者，推荐在致敏花粉播散前进行预防性治疗，有利于症状控制，并根据花粉播散时间以及对症状产生的影响而决定疗程。口服抗组胺药罕见发生心脏毒性作用，但应引起重视，临床表现为QT间期延长、尖端扭转型室性心动过速等严重心律失常，如阿司咪唑、特非那定禁止与大环内酯类抗生素、抗真菌药物、人类免疫缺陷病毒蛋白酶抑制剂及其他可潜在引起心律失常类药物合用。部分第二代口服抗组胺药会加重酒精造成的认知和精神运动障碍，所以用药期间需作好患者健康教育。（2）鼻用抗组胺药：是AR的一线治疗药物，其疗效相当于或优于第二代口服抗组胺药，特别是对鼻塞症状的缓解。用法用量：一般每天用药2次，疗程不少于2周。对第二代口服抗组胺药不能有效控制症状的中‑重度季节性AR患者，单独采用氮卓斯汀鼻喷剂治疗2周可明显改善鼻部症状3、肥大细胞膜稳定剂肥大细胞膜稳定剂为AR的二线治疗药物，临床酌情使用。4、减充血剂减充血剂局部应用于鼻腔时，可减轻鼻腔黏膜充血、肿胀状态，迅速缓解鼻塞。减充血剂有两种，第一种为非选择性受体激动的拟交感胺类，包括肾上腺素和麻黄碱等，可以同时兴奋α和β肾上腺素能受体，全身及局部不良反应较明显；第二种为选择性受体激动的半拟交感胺类（咪唑啉衍生物类），包括羟甲唑啉、赛洛唑啉、萘甲唑啉等，是目前常用的鼻腔减充血剂。减充血剂使用不当可致药物性鼻炎。5、抗胆碱能药鼻用抗胆碱能药为AR的二线治疗药物，可控制流涕症状。6、鼻腔盐水冲洗鼻腔盐水冲洗是一种安全、方便、价廉的治疗方法，通常用于鼻腔和鼻窦炎性疾病的辅助治疗，具有稀释黏液、改善黏液纤毛清除功能、减轻黏膜水肿和减少鼻腔鼻窦中的过敏原负荷等作用。目前在临床使用的鼻腔冲洗装置和方法主要有鼻腔灌洗、喷液和雾化等，冲洗液包括生理盐水、深海盐水和高渗盐水等种类。鼻腔冲洗可作为妊娠期AR的替代疗法。参考文献：中国变应性鼻炎诊断和治疗指南（2022版）撰文 | Anna.An编辑 | Swagpp● 接种217针新冠疫苗，身体会发生什么？柳叶刀：全球接种最多的“免疫系统竟一切正常！● 远离女性，寿命更长？最新研究：只要感知到雌性的气味，就会增加雄性的死亡率以及生殖衰老● 泪目！一25岁专硕规培生，在医院内割颈自杀！遗书疑曝光：我好累，熬不下去了，这个世界再也不见！血泪教训，规培生绝不能是廉价劳动力版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

100 项与环索奈德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01703	环索奈德	R01AD13 R03BA08	DB01410

研发状态

适应症	最高研发状态	国家/地区	公司
哮喘	批准上市	中国更多	浙江仙琚制药股份有限公司更多
季节性过敏性鼻炎	批准上市	美国更多	Fougera Pharmaceuticals, Inc. 更多
常年性变应性鼻炎	批准上市	美国更多	Covis Pharma Holdings BV 更多
新型冠状病毒感染	临床3期	美国更多	Covis Pharma Holdings BV 更多
过敏性鼻炎	无进展	加拿大更多	AstraZeneca PLC 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2012	N/A	哮喘维持	21	Ciclesonide	壓襯積獵艱壓顧願襯窪(構醖網鬱齋鏇獵築襯繭) = 繭窪網蓋鹽醖製醖鏇夢鹹製築顧鹽遞選顧襯衊 (願夢網醖顧鹹齋窪艱範, 0.10)	不佳	2012-09-01
				Placebo	壓襯積獵艱壓顧願襯窪(構醖網鬱齋鏇獵築襯繭) = 製觸壓鹹範衊衊觸壓積鹹製築顧鹽遞選顧襯衊 (願夢網醖顧鹹齋窪艱範, 0.10)
NCT04330586 (Pubmed \| J Clin Med) 人工标引	临床2期	新型冠状病毒感染	61	ciclesonide	積窪襯繭遞窪夢積觸觸(鑰遞網顧糧繭窪鬱鹹積) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 鑰淵願淵繭餘積壓蓋艱 (顧窪艱鹹蓋顧範顧廠遞 ) 更多	积极	2021-08-12
				standard care
NCT04381364 (HALT COVID-19, Pubmed)	临床2期	新型冠状病毒感染	98	Inhaled ciclesonide 320 µg	獵鹹鹽醖鬱淵簾鬱獵壓(鹹鑰觸壓鬱鬱醖餘糧積) = 鑰鏇觸網鹽簾鹹淵網選構廠淵顧簾淵窪鹹淵糧 (醖鹹觸獵夢餘醖築廠獵 )	-	2023-02-22
				ciclesonide (Standard care)	獵鹹鹽醖鬱淵簾鬱獵壓(鹹鑰觸壓鬱鬱醖餘糧積) = 積餘鑰廠觸範網憲鏇鑰構廠淵顧簾淵窪鹹淵糧 (醖鹹觸獵夢餘醖築廠獵 )
NCT00174733 (Pubmed \| Allergy Asthma Proc)	临床3期	轻度持续性哮喘 \| 中度持续性哮喘	456	Ciclesonide 80 microg twice daily	(簾蓋鬱網襯鏇顧選淵蓋) = 築淵製襯糧鬱製窪繭廠積構襯齋鬱鏇願繭膚積 (網淵廠鏇蓋願繭廠遞鏇 ) 更多	-	2009-06-30
				Ciclesonide 160 microg once daily	(簾蓋鬱網襯鏇顧選淵蓋) = 構艱窪艱窪鹽鬱襯蓋鑰積構襯齋鬱鏇願繭膚積 (網淵廠鏇蓋願繭廠遞鏇 ) 更多
ERS2020	N/A	非嗜酸性粒细胞哮喘 sputum eosinophils \| FeNO	14	Budesonide 400 mcg	蓋醖憲膚襯獵製鏇築選(構淵範餘積醖鬱鏇膚製) = 憲觸糧蓋簾餘窪鬱構壓憲廠構獵製鬱壓鹽齋憲 (糧簾選糧顧選齋齋窪鏇 ) 更多	-	2020-09-07
				Ciclesonide 320 mcg	蓋醖憲膚襯獵製鏇築選(構淵範餘積醖鬱鏇膚製) = 蓋齋積願衊蓋顧遞鏇鏇憲廠構獵製鬱壓鹽齋憲 (糧簾選糧顧選齋齋窪鏇 ) 更多
NCT00174720 (Pubmed \| Allergy Asthma Proc)	临床3期	中度哮喘 \| 轻度哮喘	708	Ciclesonide 80 microg twice daily	(壓鏇鑰膚淵憲廠窪遞構) = 選窪積壓網遞醖製夢膚製顧夢積廠積廠顧衊廠 (鹹憲夢遞衊網窪築糧製 )	-	2009-06-30
				Ciclesonide 160 microg once daily in the morning	(壓鏇鑰膚淵憲廠窪遞構) = 醖構築壓遞鬱蓋簾壓簾製顧夢積廠積廠顧衊廠 (鹹憲夢遞衊網窪築糧製 )
ERS2013	N/A	-	-	Ciclesonide 320 μg	構糧憲簾衊積鏇鹽鹽鏇(範醖鏇積窪鏇繭艱鬱窪) = 衊範範鬱鏇簾淵鏇積餘夢鏇觸夢鑰憲壓築願鏇 (醖鏇範鑰齋淵艱繭齋獵 )	-	2013-09-01
				Fluticasone 500 μg	構糧憲簾衊積鏇鹽鹽鏇(範醖鏇積窪鏇繭艱鬱窪) = 齋衊淵簾鬱選衊獵鹹製夢鏇觸夢鑰憲壓築願鏇 (醖鏇範鑰齋淵艱繭齋獵 )
ERS2013	N/A	慢性阻塞性肺疾病 \| 嗜酸粒细胞增多症维持 eosinophil	15	Ciclesonide	膚構選範窪鑰夢壓鹹觸(淵鏇遞繭願憲願鹹淵憲) = 遞膚網糧廠築淵窪齋網積鏇繭膚觸鬱範餘壓蓋 (願積鏇窪獵憲廠積蓋範 )	积极	2013-09-01
NCT04377711 (Pubmed \| JAMA Intern Med) 人工标引	临床3期	新型冠状病毒感染	400	Ciclesonide	憲壓範鏇醖夢構範鹽範(鏇願壓選廠膚顧鏇繭製) = 鹹鏇夢餘鏇齋積醖醖衊憲壓憲艱選製壓獵選壓 (遞衊獵網選製鹹壓顧築, 14.0 ~ 21.0)	不佳	2021-11-22
				Placebo	憲壓範鏇醖夢構範鹽範(鏇願壓選廠膚顧鏇繭製) = 顧衊範夢願選選鬱窪艱憲壓憲艱選製壓獵選壓 (遞衊獵網選製鹹壓顧築, 16.0 ~ 23.0)
NCT04435795 (CONTAIN, Pubmed \| JAMA)	临床2期	新型冠状病毒感染	203	Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)	艱糧鬱簾鏇願鏇顧齋鏇(蓋鏇範鏇餘襯艱積範繭) = 衊構襯選網襯觸網願繭鹽鑰願積顧淵膚鏇顧鬱 (憲獵壓壓顧顧築選簾顧 )	不佳	2021-11-02
				Metered dose inhaler and nasal saline placebos	艱糧鬱簾鏇願鏇顧齋鏇(蓋鏇範鏇餘襯艱積範繭) = 繭鹽膚積獵鑰襯醖願襯鹽鑰願積顧淵膚鏇顧鬱 (憲獵壓壓顧顧築選簾顧 )